Saturday 17 October 2026
Export RVMD’s income statement to Excel — free account
Revolution Medicines, Inc.
RVMD Healthcare Biotechnology
Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022. In the quarter to June 2026, EPS fell 133.6%, free cash flow fell 70.0% and total debt rose 322.7%, each against the same quarter a year earlier.
177.96
11.30
−5.97%
Follow RVMD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
11.12 | 6.59 | 6.97 | 7.86 | |
Current Ratio |
11.38 | 6.80 | 7.14 | 8.05 | |
Net Debt/EBITDA |
5.75 | 3.67 | 4.86 | 5.29 | |
Debt/Assets |
23.96% | 12.45% | 11.40% | 11.39% | |
Debt/Equity |
0.40 | 0.19 | 0.16 | 0.16 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.60 | 0.78 | 0.75 | 0.68 | |
Capex/Depreciation |
(13.69) | (1.17) | (13.01) | 2.43 | |
Interest Coverage |
(21.24) | (36.50) | (30.30) | (27.59) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.02 | 0.03 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.84) | (1.79) | (1.44) | (1.10) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.02) | |
Free Cash Flow per Share |
(1.85) | (1.80) | (1.45) | (1.11) | |
Cash per Share |
18.67 | 9.63 | 10.65 | 10.21 | |
Shareholders Equity per Share |
12.36 | 7.57 | 8.58 | 8.44 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
12.36 | 7.57 | 8.58 | 8.44 | |
Free Cash Flow |
(389.60) | (355.70) | (276.16) | (210.66) | |
Working Capital |
3,674.28 | 1,678.31 | 1,784.61 | 1,731.87 | |
Capital Expenditures |
(2.29) | (1.54) | (1.92) | (3.35) | |
Net Current Asset Value |
2,311.31 | 1,214.09 | 1,351.83 | 1,322.47 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
72.59 | 64.02 | 59.52 | 49.65 | |
Average Assets |
3,376.42 | 2,309.55 | 2,456.40 | 2,007.46 | |
Average Common Equity |
2,235.80 | 1,789.03 | 1,948.25 | 1,581.60 |
Columns are period end dates